Treatment of Serious Respiratory, Surgical and Intra-abdominal Infections in Hospitalized Patients Introduction

References

• Fadda G, Nicoletti G, Schito GC et al. Progetto nazionale per la sorveglianza delle infezioni batteriche gravi in ambito comunitario e ospedaliero. Istituto Superiore di Sanità, SIM 2004.
   Google Scholar
• Erdem I, Kaynar-Tascioglu J, Kaya B et al. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrugresistant Pseudomonas aeruginosa strains. Int J Antimicrob Agents. 2002; 20(5): 384–6.
   Google Scholar
• Novelli A, Adembri C, Livi P et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet. 2005; 44(5): 539–49.
   Google Scholar
• MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother 1997; 9 Suppl 1:64–73.
   Google Scholar
• Pea F, Brollo L, Viale P et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003; 51(4): 971–5.
   Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43(13): 925–42.
   Google Scholar
• Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37(5):1073–81.
   Google Scholar
• Lipman J, Scribante J, Gous AG et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother. 1998; 42(9): 2235–9.
   Google Scholar
• Birmingham MC, Guarino R, Heller A et al. Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. J Antimicrob Chemother. 1999; 43 Suppl A: 43–8.
   Google Scholar
• Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998; 42(3): 521–7.
   Google Scholar
• Mangram AJ, Horan TC, Pearson ML et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999; 27(2): 97–132.
   Google Scholar
• Manian FA, Meyer L. Comprehensive surveillance of surgical wound infections in outpatient and inpatient surgery. Infect Control Hosp Epidemiol. 1990; 11(10): 515–20.
   Google Scholar
• Ranaboldo CJ, Karran SE, Bailey IS et al. Antimicrobial prophylaxis in ‘clean’ surgery: hernia repair. J Antimicrob Chemother. 1993; 31 Suppl B: 35–41.
   Google Scholar
• Gupta R, Sinnett D, Carpenter R et al. Antibiotic prophylaxis for post-operative wound infection in clean elective breast surgery. Eur J Surg Oncol. 2000; 26(4): 363–6.
   Google Scholar
• Hemsell DL, Johnson ER, Hemsell PG et al. Cefazolin is inferior to cefotetan as single-dose prophylaxis for women undergoing elective total abdominal hysterectomy. Clin Infect Dis. 1995; 20(3): 677–84.
   Google Scholar
• Velanovich V. A meta-analysis of prophylactic antibiotics in head and neck surgery. Plast Reconstr Surg. 1991; 87(3): 429–34.
   Google Scholar
• Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg. 1992; 104(3): 590–9.
   Google Scholar
• De Lalla F. Surgical prophylaxis in practice. J Hosp Infect. 2002; 50 Suppl A: S9–12.
   Google Scholar
• Giacometti A, Cirioni O, Schimizzi AM et al. Epidemiology and microbiology of surgical wound infections. J Clin Microbiol. 2000; 38(2): 918–22.
   Google Scholar
• Mini E, Grassi F, Cherubino P et al. Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery. J Chemother. 2001; 13 Spec Issue 1(1): 73–9.
   Google Scholar
• Yates GL. An experimental study of the local effects of peritoneal drainage. Surg Gynecol Obstet. 1905; 1: 473–492.
   Google Scholar
• Weinstein WM, Onderdonk AB, Bartlett JG et al. Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis. 1975;132(3): 282.
   Google Scholar
• Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003; 37(8): 997–1005.
   Google Scholar
• Cohn SM, Lipsett PA, Buchman TG. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg. 2000; 232(2): 254–62.
   Google Scholar
• Wilkinson M, Woodhead MA. Guidelines for community-acquired pneumonia in the ICU. Curr Opin Crit Care. 2004; 10(1): 59–64.
   Google Scholar
• File TM. Community-acquired pneumonia. Lancet. 2003; 362(9400): 1991–2001.
   Google Scholar
• Fine MJ, Stone RA, Singer DE et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999; 159(9): 970–80.
   Google Scholar
• Ruiz M, Ewig S, Marcos MA, Martinez JA et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med. 1999 Aug;160(2):397–405.
   Google Scholar
• Mandell LA, Marrie TJ, Grossman RF et al. Canadian Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J. 2000; 7(5): 371–82.
   Google Scholar
• Mandell LA, Bartlett JG, Dowell SF et al. Update of Practice Guidelines for the Management of Community- Acquired Pneumonia in Immuno-competent Adults. Clinical Infectious Diseases 2003;37:1405–33.
   Google Scholar
• Niederman MS. Review of treatment guidelines for community-acquired pneumonia. Am J Med. 2004; 117 Suppl 3A: 51S-57S.
   Google Scholar
• Metlay JP, Hofmann J, Cetron MS et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000; 30(3): 520–8.
   Google Scholar
• Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000; 90(2): 223–9.
   Google Scholar
• Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002; 346(10):747–50.
   Google Scholar
• Vergis EN, Akbas E, Yu VL. Legionella as a cause of severe pneumonia. Semin Respir Crit Care Med. 2000; 21(4): 295–304.
   Google Scholar
• Mortensen EM, Restrepo M, Anzueto A. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med. 2004; 117(10): 726–31.
   Google Scholar
• American Thoracic Society. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia Am J Respir Crit Care Med. 2005; 171: 388–416
   Google Scholar
• Cometta A, Baumgartner JD, Lew D et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother. 1994; 38(6): 1309–13.
   Google Scholar
• Paul M, Benuri-Silbiger I, Soares-Weiser K et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br Med J. 2004; 328(7441): 668.
   Google Scholar
• Wood GC, Hanes SD, Croce MA et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002; 34(11): 1425–30.
   Google Scholar
• Polk RE, Johnson CK, McClish D et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis. 2004; 39(4): 497–503.
   Google Scholar